{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:58:37Z","timestamp":1791554317814,"version":"4.3.4"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Adaptive pharmacotherapy, ie, starting a medication regimen and then modifying that regimen based on patient response, is common in many medical domains but is not common in smoking cessation. Recently, studies have found that adaptive treatment using precessation nicotine patches is efficacious for smoking cessation; however, adaptive treatment using precessation varenicline and adaptive treatment in clinical practice settings have not been fully assessed.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether adaptive pharmacotherapy leads to higher smoking abstinence rates than standard pharmacotherapy in a clinical practice setting.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This double-blinded stratified placebo-controlled randomized clinical trial compared adaptive treatment with standard treatment for smoking cessation. The study was conducted at a university health system in Durham, North Carolina, from February 2018 to May 2020 and was stopped early due to COVID-19. Data were analyzed as intent-to-treat from May 24, 2021, to February 27, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were allowed to choose varenicline or nicotine patches and were then randomized to adaptive or nonadaptive (standard) treatment. Participants started on their chosen medication (adaptive) or placebo (standard) 4 weeks before their target quit day. Two weeks later, participants were assessed for treatment response. Adaptive participants who did not decrease daily cigarettes smoked by at least 50% (nonresponders) received bupropion in addition to their chosen medication. Participants in the adaptative treatment group who did decrease daily cigarettes smoked by at least 50% (responders) and participants in the standard treatment group received additional placebo bupropion. Participants in the standard treatment group received varenicline starting 1 week before the target quit date or nicotine patches starting on the target quit day. All participants received brief behavioral support.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The main outcome was biochemically verified 30-day continuous smoking abstinence 12 weeks after their target quit smoking day. Other measures included demographic characteristics, smoking history, and repeated smoking assessments.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the planned 300 participants, a total of 188 participants (mean [SD] age, 49.1 [12.5] years; 102 [54%] female) were enrolled before the trial was stopped because of the COVID-19 pandemic. A total of 127 participants chose to use varenicline, including 64 randomized to adaptive treatment and 63 randomized to standard treatment, and 61 participants chose to use nicotine patches, including 31 randomized to adaptive treatment and 30 randomized to standard treatment. At baseline, participants smoked a mean (SD) of 15.4 (7.3) cigarettes per day. At 12 weeks after the target quit day, biochemically verified 30-day continuous smoking abstinence was observed in 23 of 95 participants (24%) in the adaptive treatment group and 8 of 93 participants (9%) in the standard treatment (odds ratio [OR], 3.38; 95% CI, 1.43-7.99; P<\/jats:italic>\u2009=\u2009.004); among participants who used varenicline, 30-day continuous abstinence was 18 participants (28%) in the adaptive treatment group, and 5 participants (8%) in the standard treatment group (OR, 4.54; 95% CI, 1.57-13.15); among participants who used nicotine patches, 30-day continuous abstinence was 5 participants (16%) in the adaptive treatment group and 3 participants (10%) in the standard treatment group (OR, 1.73; 95% CI, 0.38-7.99). Sleep problems were more common for participants in the varenicline adaptive treatment group than in the varenicline standard treatment group (rate ratio, 1.74; 95% CI, 1.18-2.58; P<\/jats:italic>\u2009=\u2009.03).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This randomized clinical trial found that adaptive pharmacotherapy was efficacious for smoking cessation treatment in a practice setting.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02501265<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.32214","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:31:00Z","timestamp":1694187060000},"page":"e2332214","source":"Crossref","is-referenced-by-count":8,"title":["Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch"],"prefix":"10.1001","volume":"6","author":[{"given":"James M.","family":"Davis","sequence":"first","affiliation":[{"name":"Duke Center for Smoking Cessation, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke Cancer Institute, Durham, North Carolina"},{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Masclans","sequence":"additional","affiliation":[{"name":"Duke School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed E.","family":"Rose","sequence":"additional","affiliation":[{"name":"Duke Center for Smoking Cessation, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"1","key":"zoi230932r1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/med.2008.59.issue-1","article-title":"Adaptive treatment strategies in chronic disease.","volume":"59","author":"Lavori","year":"2008","journal-title":"Annu Rev Med"},{"key":"zoi230932r2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.drugalcdep.2007.02.001","article-title":"Customizing treatment to the patient: adaptive treatment strategies.","volume":"88","author":"Murphy","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"zoi230932r4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/archinternmed.2011.138","article-title":"Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.","volume":"171","author":"Hajek","year":"2011","journal-title":"Arch Intern Med"},{"key":"zoi230932r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.021","article-title":"Extending varenicline preloading to 6 weeks facilitates smoking cessation: a single-site, randomised controlled trial.","volume":"19","author":"Bohadana","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi230932r6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.280","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.","volume":"313","author":"Ebbert","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"zoi230932r7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ntr\/ntu347","article-title":"Does extended pre quit bupropion aid in extinguishing smoking behavior?","volume":"17","author":"Hawk","year":"2015","journal-title":"Nicotine Tob Res"},{"issue":"3","key":"zoi230932r8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00213-010-2069-3","article-title":"An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect.","volume":"214","author":"Lindson","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"zoi230932r9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00213-011-2350-0","article-title":"Nicotine preloading: the importance of a pre-cessation reduction in smoking behavior.","volume":"217","author":"Rose","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"zoi230932r10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1360-0443.2008.02138.x","article-title":"Nicotine patch therapy prior to quitting smoking: a meta-analysis.","volume":"103","author":"Shiffman","year":"2008","journal-title":"Addiction"},{"issue":"7-8","key":"zoi230932r11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2119\/molmed.2009.00159","article-title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","volume":"16","author":"Rose","year":"2010","journal-title":"Mol Med"},{"issue":"2","key":"zoi230932r12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1360-0443.1999.94226910.x","article-title":"Validity of the Fagerstr\u00f6m test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers.","volume":"94","author":"Etter","year":"1999","journal-title":"Addiction"},{"issue":"8","key":"zoi230932r13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1176\/appi.ajp.2013.12070919","article-title":"Adapting smoking cessation treatment according to initial response to precessation nicotine patch.","volume":"170","author":"Rose","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"3","key":"zoi230932r14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/add.1989.84.issue-3","article-title":"Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders.","volume":"84","author":"Gavin","year":"1989","journal-title":"Br J Addict"},{"issue":"4","key":"zoi230932r15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.15288\/jsa.1995.56.423","article-title":"The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings.","volume":"56","author":"Bohn","year":"1995","journal-title":"J Stud Alcohol"},{"issue":"9","key":"zoi230932r16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi230932r17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","article-title":"Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population.","volume":"46","author":"L\u00f6we","year":"2008","journal-title":"Med Care"},{"issue":"9","key":"zoi230932r18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/ntr\/ntp103","article-title":"Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.","volume":"11","author":"Rose","year":"2009","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"zoi230932r19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an a4\u00df2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"zoi230932r20","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1111\/add.2009.104.issue-12","article-title":"Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) four country survey.","volume":"104","author":"Herd","year":"2009","journal-title":"Addiction"},{"issue":"1","key":"zoi230932r21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/add.2004.99.issue-1","article-title":"Shape of the relapse curve and long-term abstinence among untreated smokers.","volume":"99","author":"Hughes","year":"2004","journal-title":"Addiction"},{"issue":"4","key":"zoi230932r24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/tobaccocontrol-2021-056843","article-title":"Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders.","volume":"32","author":"Talukder","year":"2023","journal-title":"Tob Control"},{"issue":"11","key":"zoi230932r27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","article-title":"Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.","volume":"171","author":"Rose","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi230932r28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jama.2013.283185","article-title":"Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.","volume":"311","author":"Ebbert","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"zoi230932r29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis.","volume":"2013","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi230932r3","volume-title":"Treating Tobacco Use and Dependence: 2008 Update","author":"Tobacco Use and Dependence Guideline Panel","year":"2008"},{"key":"zoi230932r22","unstructured":"Centers for Disease Control and Prevention. National Health Interview Survey. Accessed February 20, 2023. https:\/\/www.cdc.gov\/nchs\/nhis\/index.htm"},{"key":"zoi230932r23","unstructured":"American Lung Association. Behavioral health & tobacco use. Accessed February 20, 2023. https:\/\/www.lung.org\/quit-smoking\/smoking-facts\/impact-of-tobacco-use\/behavioral-health-tobacco-use"},{"key":"zoi230932r25","unstructured":"US Census Bureau. QuickFacts: United States. Accessed November 8, 2022. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045221"},{"key":"zoi230932r26","unstructured":"Centers for Disease Control and Prevention. Burden of cigarette use in the U.S. Accessed January 7, 2023. https:\/\/www.cdc.gov\/tobacco\/campaign\/tips\/resources\/data\/cigarette-smoking-in-united-states.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809121\/davis_2023_oi_230932_1693333246.3146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:31:04Z","timestamp":1694187064000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809121"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.32214","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}